Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate. Palombo-Kinne E, Schellschmidt I, Gräser T. Contraception 2009; 79: 282-289 A recent Cochrane Review found that combined oral contraceptives (COCs) reduced acne lesion counts, severity grades and self-assessed acne compared to placebo. 1 However, differences in the comparative effectiveness of COCs with varying progestin types and dosages were less clear.
Presently the treatment regimen for termination of early pregnancy (less than 63 days gestation) in the UK comprises 200 mg mifepristone orally followed by 800 µg misoprostol vaginally 36-48 hours later. Although unlicensed, these are the guidelines from the Royal College of Obstetricians and Gynaecologists (2004) for regimens for inducing medical abortion. The mifepristone works to soften and dilate the uterine cervix and sensitise the myometrium prior to use of the prostaglandin analogue, misoprostol. Pharmacokinetic studies suggest that oral administration of 100 mg or higher single doses of mifepristone result in similarly efficacious serum concentrations. Data available regarding the interval between treatments suggest that the efficacy is highest when the interval is 48 hours. No research studies previously have investigated the time interval between doses, or the comparison of 100 mg with 200 mg doses of mifepristone.
This study had four treatment arms (mifepristone 100 mg orally followed by 800 µg misoprostol vaginally either 24 or 48 hours subsequently, and mifepristone 200 mg followed by 800 µg misoprostol after 24 or 48 hours) to which 2126 women were randomised, across 13 obstetric and gynaecology departments in nine countries. Through a thorough selection protocol almost equal numbers (with significant similarities for age, gravidity and previous terminations) were recruited to each arm across all sites; randomisation was achieved by utilisation of an international sequence produced by the World Health Organization in Geneva. The double-blind trial was well designed and powered with a low attrition rate (55 from 2181 women). Even those patients lost to follow-up are counted as failures of method when in fact they may have had complete abortions. Internal validity was achieved by randomisation and a required confidence interval of 95% for the difference in complete abortion rates -the margin of equivalence of 5% having been chosen using the researchers' clinical judgement. External validity was demonstrated as women were enrolled from several different populations and included clinicians with different levels of experience of medical abortions.
The primary outcome measure was efficacy of the treatment in inducing complete abortion in all arms. The study found that both doses and both administration intervals are equivalent when the gestational age is 49 days or less, and results were inconclusive when the gestational age is 50 days or more. The findings show similar efficacy for complete abortion with both mifepristone doses and both treatment intervals. Despite the maximal sensitivity of mifepristone administration previously being demonstrated at 36-48 hours before the prostaglandin analogue use, this study found the 24-hour interval to have lower failure rates than the 48-hour interval group. Also both mifepristone doses produced equivalent rates of failure to achieve complete abortion within each interval of misoprostol administration. Reports of side effects were lower in the 24-hour interval group, suggesting this regimen could be better tolerated and provide a more pleasant patient experience. Overall conclusions are that the dose of mifepristone could be lowered to 100 mg and the administration interval between that and 800 µg misoprostol could be shortened to 24 hours without detrimental effect when terminating early pregnancy. This could have many repercussions in termination service including reducing cost implications of higher doses and the provision of well-tolerated regimes.
Reviewed by Rebecca Pullen, BSc Contains not more than 50 mg lactose per tablet, which should be considered for patients with intolerance to certain sugars. Include personal and family medical history and physical examination as part of assessment prior to treatment. Blood pressure should be measured and a physical examination should be performed, guided by the contraindications and warnings. The frequency and nature of examinations should be based on established practice guidelines and adapted to the individual woman. Investigate bleeding irregularities that occur after regular cycles. Certain conditions, such as cardiac or renal dysfunction and diabetes during initial usage, require strict medical supervision. Interactions: Interaction with specific drugs will necessitate additional non-hormonal contraceptive measures. Qlaira may affect the metabolism of other medicines. Lab tests may be affected. The prescribing information of concomitant drugs should be consulted to identify potential interactions. Pregnancy and lactation: Qlaira should not be used during pregnancy or recommended during lactation. Effects on ability to drive and use machines: Qlaira has no influence on the ability to drive or use machines. Undesirable effects: Common -Headache (including tension headache), abdominal pain (including abdominal distension), acne, amenorrhea, dysmenorrhea, intracyclic bleeding (metrorrhagia), breast discomfort, weight increase. Serious side effects cf. CI/Warnings and Precautions -in addition hypertension, cervical dysplasia, migraine, uterine leiomyoma, genital hemorrhage, presumed ocular histoplasmosis syndrome, ruptured ovarian cyst. In addition to the above mentioned adverse reactions, erythema nodosum, erythema multiforme, breast discharge and hypersensitivity have occurred under treatment with ethinylestradiol-containing COCs (although these symptoms were not reported during the clinical studies performed with Qlaira, the possibility that they also occur under treatment cannot be ruled out). Other side effects -Prescribers should consult the SmPC in relation to other side effects. Overdose: There have been no reports of serious deleterious effects from overdose. Symptoms that may occur in case of taking an overdose of active tablets are: nausea, vomiting and, in young girls, slight vaginal bleeding. There are no antidotes and further treatment should be symptomatic. 
